Regulator
The FDA cleared Parker Hannifin's Indego exoskeleton (510(k) K152416) for people with lower spinal cord injuries, at home with a trained companion, and for people with higher injuries in rehab centres. It is not meant for stairs.
A regulator's decision · Sets Medical exoskeletons's stage
What the source says
“individuals with spinal cord injury at levels T7 to L5 to perform ambulatory functions”
What it means
Medical exoskeletons, from Lifeward (ReWalk), Wandercraft, Ekso Bionics (owned by Wandercraft since Oct 2026), is at stage 5 of 5 on our ladder: regulator-cleared or mass market. This event is one of the milestones that placed it there.
Human help: A staff member rides along, ready to stop it.
More on Medical exoskeletons
- Wandercraft bought Ekso Bionics from ChronoScale and said it would keep supporting Atalante X, EksoNR, Eve and Indego Personal. The price was not disclosed.
- Wandercraft said the FDA cleared Eve, a self-balancing exoskeleton for personal use, for adults with spinal cord injuries at any level, used with a trained companion.
- Ekso's parent company, renamed ChronoScale and moving into cloud computing, said it would sell the Ekso exoskeleton business.
- The FDA cleared the ReWalk 7 Personal Exoskeleton from Lifeward (510(k) K241822) for indoor and outdoor walking, including stairs and curbs.
- Medicare set a payment rate for personal exoskeletons for home use, starting with the ReWalk Personal and the Indego Personal.
- Ekso Bionics bought the Indego exoskeleton business from Parker Hannifin for $10 million.